Leo is routinely the worst PR guy on the planet. I just don't get it. If he was simply reserved and cautious then he wouldn't keep dropping these absurdly fluffy PRs but when we do finally get good news I feel like i'm reading and obitutary.
What does this PR mean besides that the trial is over?
Keep in mind I am a moron but here's my guess:
Bioequivilance is usually used to measure generic drugs against their brand name counterparts.
result: Prurisol converted to abacavir in the body (the intention) within a range that made it equivalent to taking Ziagen (brand name abacavir).
Here is the note in the study:
Part B of the study will determine the average bioequivalence of abacavir derived from Prurisol (abacavir acetate) 350mg compared with abacavir derived from the commercially available tablet formulation of Ziagen (abacavir sulfate) 300mg. After completion of Part A, subjects will be randomly assigned to cross-over treatment sequence Prurisol then Ziagen, or Ziagen then Prurisol. Five to 21 days later, each subject will receive the alternate study drug. Evaluable subjects in the PK population will be those who received both alternate treatments and for whom an adequate number of post-dose PK sample results are available.
My understanding is that since the body is converting it it has a different impact on immo-response despite resulting in a "bioequivilent" drug.
Interestingly enough Ziagen is owned by ViiV healthcare, an HIV focused collaboration which is 75% owned by Glaxo...
Market Data 
Markets 
AI
